Drug Eluting Balloons Market

Increasing Prevalence of Coronary Artery Disease is Projected to Drive Market Growth

The increasing prevalence of coronary artery disease and diabetes is likely to drive market CAGR in the drug eluting balloon over the forecast period. Drug-eluting balloons are angioplasty balloons that play an important role in the treatment of coronary heart disease. The high prevalence of coronary artery disease is likely to increase demand for angioplasty and other therapies, hence driving market expansion. According to the World Health Organization (WHO), coronary heart disease kills approximately 3.8 million men and 4.4 million women each year.

Furthermore, the number of fatalities between the ages of 15 and 59 is estimated to reach 1332 million, with an additional 5825 million occurring after the age of 60.

Additionally, diabetes can damage blood vessels and neurons in the heart, which can lead to cardiovascular disease. As a result, the increasing prevalence of diabetes is likely to drive growth in the medication-eluting balloon market throughout the forecast period. For example, according to the World Health Organization's October 2018 report, diabetes causes approximately 1.6 million deaths worldwide. According to the Centers for Disease Control and Prevention, 537 million adults (20-79 years old) worldwide had diabetes in 2021, accounting for one in every ten people.

China has the world's biggest number of diabetics, with over 141 million individuals suffering from the condition. By 2045, China is expected to have over 174 million diabetics.

In addition, according to the Centers for Disease Control and Prevention, the highest prevalence of diagnosed diabetes in 2019 was among American Indians and Alaska Natives (14.5%), followed by non-Hispanic Blacks (12.1%), people of Hispanic origin (11.8%), non-Hispanic Asians (9.5%), and non-Hispanic Whites. According to the World Health Organization, 3.1 million persons aged 20 and up, or 10.8% of all adults in the United States with diabetes, began using insulin within a year of being diagnosed. Thus driving the Drug Eluting Balloons Market revenue.

The Global Drug Eluting Balloons Market Industry is projected to experience substantial growth in the coming years, with estimates indicating a rise from 0.66 USD Billion in 2024 to 1.37 USD Billion by 2035. This growth trajectory reflects the increasing adoption of drug eluting balloons in various clinical applications, driven by advancements in technology and rising patient demand for effective cardiovascular treatments. The anticipated CAGR of 6.84% from 2025 to 2035 further underscores the market's potential, suggesting a robust future for drug eluting balloon technologies as they become integral to modern cardiovascular care.

The demographic shift towards an aging population globally is a crucial driver for the Global Drug Eluting Balloons Market Industry. Older adults are more susceptible to cardiovascular diseases, leading to an increased demand for effective treatment options. This demographic trend is expected to create a substantial market opportunity, as healthcare systems adapt to the needs of this population. By 2035, the market is projected to grow to 1.37 USD Billion, highlighting the potential for drug eluting balloons to address the unique healthcare challenges faced by the elderly.

Regulatory bodies worldwide are increasingly supportive of the development and approval of drug eluting balloons, which is a significant driver for the Global Drug Eluting Balloons Market Industry. Streamlined approval processes and favorable regulatory frameworks facilitate the introduction of new products into the market. This regulatory environment encourages innovation and competition among manufacturers, ultimately benefiting patients through improved treatment options. The ongoing support from regulatory agencies is expected to bolster market growth, as companies are motivated to invest in research and development of advanced drug eluting balloon technologies.

Technological innovations in the field of medical devices significantly contribute to the expansion of the Global Drug Eluting Balloons Market Industry. Advancements such as improved balloon materials, enhanced drug formulations, and sophisticated delivery systems are enhancing the efficacy and safety of these devices. These innovations not only improve clinical outcomes but also increase the adoption rates among healthcare professionals. As the market evolves, it is anticipated that the industry will witness a compound annual growth rate (CAGR) of 6.84% from 2025 to 2035, reflecting the positive impact of technology on market dynamics.

The rising incidence of cardiovascular diseases globally drives the demand for innovative treatment options, including drug eluting balloons. As per recent statistics, cardiovascular diseases remain a leading cause of mortality worldwide, necessitating advanced therapeutic interventions. The Global Drug Eluting Balloons Market Industry is poised to benefit from this trend, with the market projected to reach 0.66 USD Billion in 2024. This increasing prevalence underscores the need for effective solutions that can enhance patient outcomes and reduce the risk of restenosis, thereby propelling the growth of the drug eluting balloon segment.

There is a notable increase in awareness and acceptance of minimally invasive procedures among patients and healthcare providers, which is positively influencing the Global Drug Eluting Balloons Market Industry. Patients are increasingly seeking less invasive treatment options that promise quicker recovery times and reduced hospital stays. This shift in patient preference is encouraging healthcare providers to adopt drug eluting balloons as a viable alternative to traditional surgical methods. As a result, the market is likely to experience sustained growth, driven by the demand for innovative and patient-friendly treatment solutions.

By region, the study provides the market insights into North America, Europe, Asia-Pacific and the Rest of the World. North America dominated the Drug Eluting Balloons Market in 2023, accounting for 45.80%. Several factors contribute to North America's considerable market share, including the availability of a variety of major manufacturers, the introduction of new, technologically advanced devices, and favorable reimbursement policies. The American Heart Association estimates that over 500,000 percutaneous coronary treatments, including percutaneous transluminal coronary interventions, are performed annually in the United States. Furthermore, increased government spending on health care in the United States is driving market growth.

Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: DRUG ELUTING BALLOONS MARKET SHARE BY REGION 2023 (USD Billion)

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Europe Drug Eluting Balloons Market accounts for the second-largest market share. This is due to an increasing prevalence of cardiovascular diseases such as coronary artery disease, heart valve disease, arrhythmia, heart failure, peripheral disorders, and renal failure, among others. Further, the German Drug Eluting Balloons Market held the largest market share, and the UK Drug Eluting Balloons Market was the fastest-growing market in the European region.

The Asia-Pacific Drug Eluting Balloons Market is expected to grow at the fastest CAGR from 2024 to 2032. This can be attributed to rising healthcare costs and an increase in the prevalence of cardiovascular diseases. Moreover, China’s Drug Eluting Balloons Market held the largest market share, and the Indian Drug Eluting Balloons Market was the fastest-growing market in the Asia-Pacific region.

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Drug Eluting Balloons Market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Global Drug Eluting Balloons industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the Global Drug Eluting Balloons industry to benefit clients and increase the market sector. In recent years, the Global Drug Eluting Balloons industry has offered some of the most significant advantages to medicine. Major players in the Drug Eluting Balloons Market, including Bayer AG, Medtronic, B. Braun Melsungen AG, Cook Medical, Inc., Boston Scientific Corporation and others, are attempting to increase market demand by investing in research and development operations.

Medtronic plc is an Irish medical device corporation. The company's operational and management offices are in Minneapolis, Minnesota, while its legal headquarters are in Ireland, following its 2015 acquisition of Irish-based Covidien. While it is based in the United States, it operates in over 150 countries and employs over 90,000 people. It creates and manufactures healthcare technologies and treatments. In July 2021, Medtronic plc introduced the Prevail™ Drug-Coated Balloon (DCB) Catheter, the next-generation catheter in Europe. It uses fast medication absorption to treat restricted or blocked coronary arteries in patients with coronary artery disease.

Boston Scientific Corporation is a biomedical/biotechnology engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, such as interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology, and gynecology. Boston Scientific is widely recognized for developing the Taxus Stent, a drug-eluting stent used to unblock clogged arteries. Cameron Health was fully acquired in June 2012, and the firm became well-known for delivering a minimally invasive implantable cardioverter-defibrillator (ICD) known as the EMBLEM subcutaneous implantable defibrillator (S-ICD). In November 2020, The FDA approved Boston Scientific's Ranger Drug-Coated Balloon.

These catheters are used to treat patients with superficial femoral artery (SFA) and proximal popliteal artery peripheral vascular disease (PAD). This approval gives the company an advantage over its competitors in the market for drug-eluting balloon catheters.